Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The FDA approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s ...

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

Panel members had questions about whether a new FDA proposal to require randomized trials for vaccines in healthy adults ...

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Vaccination rates across the country have continued to fall since the height of the pandemic, but the coronavirus never ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...